Bibliografías temáticas / Tong xin zhong xue

Literatura académica sobre el tema "Tong xin zhong xue"

Autor: Grafiati
Publicado: 26 de julio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Índice

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Tong xin zhong xue".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Tong xin zhong xue"

1

Li, Zhuo, Liang Qu, Xin Chen, Liu Xue, Jie Li, Qi Liu, Jian Sun et al. "Abstract 2371: BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and < for vivo antitumor activity and < for superior safety profile in preclinical models". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 2371. http://dx.doi.org/10.1158/1538-7445.am2024-2371.

Texto completo
Resumen
Abstract 4-1BB (CD137) is a key costimulatory immunoreceptor and a promising therapeutic target in cancer. CEACAM5 (CEA) is a well-established tumor associated antigen overexpressed in many cancers, including colorectal, gastric, lung, pancreatic cancer, liver, breast and thyroid cancers. BGB-B167 is a novel immunoglobulin G (IgG)-based bispecific antibody targeting 4-1BB and CEA and is under clinical development for the treatment of advanced or metastatic solid tumors in humans. BGB-B167 binds to its target proteins with high specificity and affinity. Potent and CEA-dependent functional activities were demonstrated using peripheral blood mononuclear cell (PBMC)-based immune cell activation and cytotoxicity assays. In humanized 4-1BB knock-in mice bearing human CEA-expressing tumors, BGB-B167 exhibited potent, dose-associated single-agent efficacy as well as synergistic antitumor activity in combination with anti-PD-1 antibody. BGB-B167 was well tolerated in 1-month repeat-dose toxicology study in cynomolgus monkeys. Here, we describe the characterization of BGB-B167 with regard to preclinical proof-of-concept and basic drug-like properties. The combined dataset provides an overview on the design, mode of action, preclinical pharmacology and safety profile of BGB-B167. Citation Format: Zhuo Li, Liang Qu, Xin Chen, Liu Xue, Jie Li, Qi Liu, Jian Sun, Hanzi Sun, Yun Chen, Yuanyuan Xie, Wanyi Wang, Lin Zhu, Penghao Wang, Xiaosui Zhou, Hongjia Hou, Jie Chen, Xinyi Liu, Yilu Zhang, Ning Liu, Xinyi Liang, Shuo Zhang, Xiaoyan Tang, Jing Song, Tong Zhang, Xiaomin Song, Xuesong Liu, Kang Li, Chichi Huang. BGB-B167, a first-in-class 4-1BB/CEACAM5 bispecific antibody, exhibits potent in vitro and < for vivo antitumor activity and < for superior safety profile in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2371.
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Zhu, Xiu-Zhi, Xi Jin, Hu-Yun-Long Zhang, Xiyu Liu, Yi-Fan Zhou, Yi-Yu Chen, Tong Fu et al. "Abstract PO1-15-07: Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial". Cancer Research 84, n.º 9_Supplement (2 de mayo de 2024): PO1–15–07—PO1–15–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-15-07.

Texto completo
Resumen
Abstract Background: The standard approach of using one-size-fits-all endocrine therapy for hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancers has faced significant challenges due to variations in treatment response among individuals. Consequently, there is still an urgent need to understand the molecular biology of HR+/HER2- breast cancer and explore precision treatment strategy. Methods: We established a multiomics cohort (n = 351), multicenter real-world clinical cohorts (n = 643), a prospective clinical cohort (MULAN trial), and a drug-testing platform containing patient-derived organoids (n = 126) and patient-derived tumor fragments (n = 49) of HR+/HER2- breast cancers. Integrating "bench" and “bedside” data, we conducted comprehensive preclinical and clinical translational research on precision strategies in HR+/HER2- breast cancer. Results: We implemented a comprehensive classification system for HR+/HER2- breast cancer, comprising four distinct subtypes. We further demonstrated the efficacy and mechanisms of subtyping-directed precision treatment strategies through clinical cohort studies, omics analysis and functional assays: endocrine therapy alone for the canonical luminal subtype; the addition of CDK4/6 inhibitor and PARP inhibitor for the proliferative subtype; the immunotherapy for the immunogenic subtype; and tyrosine kinase inhibitors for the receptor tyrosine kinase-driven subtype. Using clinically applicable subtyping methods, we validated that matched precision treatment strategies outperformed unmatched approaches in a real-world cohort, almost doubling the median progression-free survival time for patients with refractory advanced HR+/HER2- breast cancer (9.83 months [95% CI, 5.74-13.93] vs 4.77 months [95% CI, 3.35-6.18]; hazard ratio 0.64 [95% CI, 0.41-0.99]). Importantly, the first-stage analysis of the MULAN phase II umbrella clinical trial (NCT04355858) verified the higher objective response rate (88.9%, 95%CI: 51.7%-99.7%) of the subtyping-directed precision treatment. Conclusion: Our study emphasizes the superiority of subtyping-directed precision treatment strategies for HR+/HER2- breast cancer, refines traditional “one-size-fits-all” therapy, and facilitates the translation of precision treatment strategies from bench to bedside. Overall study design Part 1 Subtype Molecular Characteristics: Molecular features of the four subtypes of HR+/HER2- breast cancer. Part 2 Multidimensional Efficacy Validation: Integrating data from a multiomics cohort, real-world study, drug testing platform and prospective clinical research to validate the subtyping-directed precision treatment strategy in HR+/HER2- breast cancer. Part 3 Subtyping-directed Precision Treatment Strategy: Integrating clinical cohort studies, omics analysis and functional assays revealed the heterogeneity of treatment response in HR+/HER2- breast cancer, and proposed a subtyping-directed precision treatment strategy. CIN, chromosomal instability; RTK, receptor tyrosine kinase; CNA, copy-number alteration; ER, estrogen receptor; HR, hormone receptor; HER2, human epidermal growth factor receptor 2. Citation Format: Xiu-Zhi Zhu, Xi Jin, Hu-Yun-Long Zhang, Xiyu Liu, Yi-Fan Zhou, Yi-Yu Chen, Tong Fu, Ming-Liang Jin, Ya-Xin Zhao, Yi-Fan Xie, Ruo-Xi Wang, Zhong-Hua Wang, Lei Fan, Yi-Zhou Jiang, Zhi-Ming Shao. Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-15-07.
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Xu, Yuan, Shan Cao, Shu-fei Wang, Xin-li Hou, Si-si Guo y Xiao-jun Gou. "Comparative efficacy and safety of Chinese patent medicines of acute ischemic stroke: A network meta-analysis". Medicine 102, n.º 42 (20 de octubre de 2023): e35129. http://dx.doi.org/10.1097/md.0000000000035129.

Texto completo
Resumen
Background: Acute ischemic stroke (AIS) is characterized by high morbidity, disability, mortality, recurrence, and economic burden. Clinical trials have demonstrated that the clinical efficacy of combining oral Chinese patent medicines (CPMs) with chemical drugs (CDs) is better than that of CDs alone. In this study, we performed a network meta-analysis (NMA) of RCTs to assess the efficacy of different CPMs in combination with CDs in the treatment of AIS. Methods: Search 6 databases from the beginning to January 10, 2023. The Cochrane Risk of Bias tool assessed the methodological quality of the included studies. The NMA was then performed using the STATA 13.0 program. The surface under the cumulative ranking curve (SUCRA) probability values were applied to rank the studied treatments, and cluster analysis was used to compare the effects of CPMs between 2 different outcomes. Results: A total of 94 eligible RCTs, involving 9581 participants, were included in this analysis. Nine CPMs, including Nao-mai-li granule (NML), Nao-mai-tai granule (NMT), Qi-long granule (QL), Long-sheng-zhi capsule (LSZ), Nao-xin-tong capsule (NXT), Nao-xue-shu oral liquid (NXS), Tong-xin-luo capsule (TXL), Xiao-shuan-chang-rong capsule (XSCR), and Xue-shuan-xin-mai-ning capsule (XSXMN) were included. Regarding the clinical effective rate, all types of CPMs + CDs treatments were significantly better than CDs treatments alone, with significant differences among the 9 selected CPMs. Compared with CDs, results showed that NXS + CDs performed best in improving clinical effective rate [OR = 4.73; 95% CI: 1.26–17.78; (SUCRA: 76.1%)]. TXL + CDs showed the most effective effect in alleviating National Institutes of Health Stroke Scale (NIHSS) [MD = −3.84; 95% CI: −5.23, −2.45; (SUCRA: 81.6%)]; NXT + CDs were most effective in improving Barthel index [MD = 13.05; 95% CI: 3.98–22.12; (SUCRA: 63.5%)]. Combined with other outcome indicators and the results of cluster analysis, NXS + CDs may assist in the potential optimal treatment regimen for AIS. Conclusion: In conclusion, CPMs were found to be beneficial as adjuvant therapy in patients with AIS. Taking into account the clinical effective rate and other outcomes, NXS + CDs may be the most effective option to improve the condition of AIS patients.
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

YOUN, Sangsoo. "A Study on Jujaeonrondongeego(朱子言論同異攷): Especially Focusing on the Section Dealing with Ren Xin Dao Xin(人心道心) in Shujing(書經)". Tae Dong Institute of classic research 51 (31 de diciembre de 2023): 291–316. http://dx.doi.org/10.31408/tdicr.2023.51.291.

Texto completo
Resumen
In this paper, I have examined whether the three methods elucidated by Han Won-jin in the preface of Jujaeonrondongeego(朱子言論同異攷)—namely, the verification of the time of writings, mutual comparison of relevant remarks, and judgment based on theoretical consistency—successfully achieve the purpose of this book, which aims to confirm the final conclusion of Zhu Xi(朱熹), especially focused on the part of dealing with Ren Xin Dao Xin (人心道心) of Shujing(書經). Although it may sound somewhat conventional, it seems inevitable to acknowledge that this book also has both achievements and limitations. In ‘Ren Xin Dao Xin(人心道心)’, the distinction between the early theory and the final conclusion of Zhu Xi, the rejection of ｢Answer to Cai Ji-tong(答蔡季通)｣ in favor of ｢Answer to Zheng Zi-shang(答鄭子上)｣, and the demonstration that the ‘Xing Qi(形氣)’ mentioned in the preface of Zhong Yong Zhang Ju(中庸章句) refers to the body, based on ｢Answer to Chen An-qing(答陳安卿)｣ and others, undoubtedly represent the achievements of this book. On the other hand, it is also true that there were certain limitations in establishing Zhu Xi's final conclusion based on theoretical consistency. Han Won-jin seems to have been aware of these limitations himself. And he appears helpless when confronted with remarks expressing the early theory despite his later writings. Moreover, he might not have been able to effectively criticize those who used this as the basis for their arguments. In this regard, it is difficult to say that the purpose of this book, which was to distinguish between the early theory and the final conclusion and to demonstrate that his own and his school's doctrines are consistent with Zhu Xi's final conclusion, has also been successfully realized. As Han Won-jin mentioned, the decisions regarding what to accept and what to reject from this book will ultimately be left to the reader's judgment.
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Xiao, Rui. "Yi Zhong Qiu Tong: Zhong Guo Dang Dai Yi Xue Shu Yu De Dong Tai Xing Cheng [Seeking Understanding from Differences: The Dynamic Formation of Chinese Contemporary Translation Terminology]". Australian Journal of Linguistics 39, n.º 2 (21 de mayo de 2017): 271–75. http://dx.doi.org/10.1080/07268602.2017.1311293.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Kim, Sang-hyun. "The Theory of Xin-tong-xing-qing(心統性情) through The Debate on Zhong-he(中和論辨)". Journal of Korean Philosophical Society 149 (28 de febrero de 2019): 29–61. http://dx.doi.org/10.20293/jokps.2019.149.29.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Li, Chenyang y Wang Shanbo [wang][shan][bo]. "Zhuiqiu kexue jingshen: Zhong-Xi kexue bijiao yu rongtong de zhexue toushi [zhui][qiu][ke][xue][jing][shen] : [zhong][xi][ke][xue][bi][jiao][yu][rong][tong][de][zhe][xue][tou][shi] (Seeking the Soul of Science: Science in China and the West Compared through an Understanding of Philosophical Perspective)". Philosophy East and West 49, n.º 1 (enero de 1999): 86. http://dx.doi.org/10.2307/1400122.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Xie, Yunong, Minghe Zhang, Yan Liu, Linglin Liu, Alfred Sze-Lok Cheng, Stephanie Ma y Man Tong. "Abstract 4667: HDAC9 as a potential regulator of lenvatinib resistance in hepatocellular carcinoma". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 4667. http://dx.doi.org/10.1158/1538-7445.am2024-4667.

Texto completo
Resumen
Abstract Lenvatinib is used as the first-line therapy for advanced hepatocellular carcinoma (HCC) patients. However, poor response and compromised therapeutic effect with prolonged treatment are frequently observed in HCC patients. To elucidate the underlying mechanisms, lenvatinib responsive and non-responsive stages were modeled in liver tumor-bearing immunocompetent mice which were divided into lenvatinib and vehicle control treatment groups. Tumor tissues after short and prolonged lenvatinib treatment were harvested for single-cell RNA sequencing. Results from single-cell RNA sequencing revealed heterogenous tumor cell sub-populations associated with tumor differentiation and identified an upregulated expression of class IIa histone acetylase HDAC9 in lenvatinib-treated tumor at the non-responsive stage. Upregulation of HDAC9 was similarly observed in lenvatinib-resistant human patient-derived xenograft (PDX). Functional studies suggested that suppressing HDAC9 could re-sensitize lenvatinib response in both in vitro and in vivo models. In sum, we identified a potential regulator of lenvatinib treatment response in HCC. Citation Format: Yunong Xie, Minghe Zhang, Yan Liu, Linglin Liu, Alfred Sze-Lok Cheng, Stephanie Ma, Man Tong. HDAC9 as a potential regulator of lenvatinib resistance in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4667.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Lv, He, Zhe Feng, Xingyu Chen, Zhenyu Zhang, Tianhao Zhou, Jihu Wei, Lin Feng, Yizi Tao, Feng Chen y Shijin Lu. "Global scientific trends on exosomes therapy for osteoporosis from 2004 to 2023: A bibliometric and visualized analysis". Medicine 103, n.º 28 (12 de julio de 2024): e38835. http://dx.doi.org/10.1097/md.0000000000038835.

Texto completo
Resumen
Background: Exosomes have emerged as pivotal mediators in modulating physiological and pathological processes implicated in osteoporosis (OP) through their distinctive mode of intracellular communication. The use of exosomes has evoked considerable interest, catalyzing a surge in research endeavors on a global scale. This study endeavors to scrutinize contemporary landscapes and burgeoning trends in this realm. Methods: The Web of Science Core Collection was used to retrieve publications on exosomes therapy for OP within the time frame of January 1, 2004 to December 31, 2023. The bibliometric methodology was applied to study and index the collected data. VOSviewer and citespace software were used to conduct visualization, co-authorship, co-occurrence, and publication trend analyses of exosome therapy in OP. Results: A total of 610 publications (443 articles and 167 reviews) from 51 countries and 911 institutions were included in this study. Shanghai Jiao Tong University, Central South University, Sichuan University, and Zhejiang University are leading research institutions in this field. Stem Cell Research Therapy published the highest number of articles and has emerged as the most cited journal. Of the 4077 scholars who participated in the study, Xie, Hui, Zhang, Yan, Tan, and Yi-Juan had the largest number of articles. Furthermore, according to the cluster analysis of external keywords, future research hotspots can be categorized into 3 directions: research status of exosomes for the treatment of OP, treatment of OP through exosome-regulated signaling pathways, and exosomes as targeted drug delivery systems. Conclusion: This study suggests that the number of future publications on exosome therapy for OP will increase, with a focus on fundamental investigations into drug-loading capacities and molecular mechanisms. In summary, this study presents the first systematic bibliometric analysis of exosome therapy publications in OP, providing an objective and comprehensive overview of the field and a valuable reference for researchers in this domain.
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Wang, Zuoyue. "Jian Zhang. Ke xue she tuan zai jin dai Zhongguo de ming yun: yi Zhongguo ke xue she wei zhong xin [The Science Association and the Change of Society in Modern China: A Study on the Science Society of China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 460 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥49 (paper)." Isis 99, n.º 2 (junio de 2008): 437–38. http://dx.doi.org/10.1086/591376.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Tesis sobre el tema "Tong xin zhong xue"

1

Huang, Shaofen. "Zhen ci dui ying ji fan ying zhong xue ya he xin shuai de ying xiang ji qi ji li tan tao : wen xian zong shu /". click here to view the abstract and table of contents, 2006. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b20009537a.pdf.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Chan, Lai-ying Joyce. "Gao zhong xue sheng kou yu gou tong de xian jie neng li yan jiu". Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B4255357X.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Mao, Jian. "San si shi nian dai Shanghai wen xue yu dian ying zhong de dou shi xin gan jue". online access from Digital dissertation consortium, 2002. http://libweb.cityu.edu.hk/cgi-bin/er/db/ddcdiss.pl?3067170.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Pau, Chung-chee Bruno. "A study of Li Zhi's thought : with special reference to his "tongxin shou" = Li Zhi si xiang yan jiu : yi "tong xin shuo" wei zhong xin /". Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38598541.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Zhang, Zhuan. "Xin wen zhuan ye zhu yi zai Zhongguo : "xin wen tiao cha" ge an yan an = Professionalism at work : the case of "New Probe" /". click here to view the abstract and table of contents, 2003. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b17563379a.pdf.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Yeung, Wai-sze. "Cross-subject implementation and assessment of modern Chinese poetry in Hong Kong secondary schools Zhong xue xin shi kua xue ke ke cheng de shi jian yu ping gu /". Click to view the E-thesis via HKUTO, 2006. http://sunzi.lib.hku.hk/hkuto/record/B37341145.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Mu, Jian. "Zhuzi de shi li guan ji qi yu li de guan xi zhi yan jiu : yi Zhuzi "Si shu" xue wei zhong xin /". View abstract or full-text, 2008. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202008%20MU.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Lau, Ming-yan. "Dissemination strategies for the newly revised Chinese language curriculum in Hong Kong = Xiang Gang zhong xue Zhong Guo yu wen ke xin xiu ding ke cheng de tui guang ce lüe /". Hong Kong : University of Hong Kong, 2002. http://sunzi.lib.hku.hk/hkuto/record.jsp?B25754816.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Ho, Miu-chun Michelle. "The application of systemic functional linguistics to teaching individual brief narrative speaking to junior secondary students Xi tong gong neng yu yan xue zai chu zhong ji shi duan jiang jiao xue de ying yong /". Click to view the E-thesis via HKUTO, 2006. http://sunzi.lib.hku.hk/hkuto/record/B37520350.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Zhang, Jian. "Ke xue she tuan zai jin dai Zhongguo de ming yun yi Zhongguo ke xue she wei zhong xin = The science association and the change of society in modern China : a study on The science society of China /". Jinan Shi : Shandong jiao yu chu ban she, 2005. http://catalog.hathitrust.org/api/volumes/oclc/64694546.html.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Libros sobre el tema "Tong xin zhong xue"

1

Xin wen yu da zhong chuan mei tong lun. Beijing: Zhongguo ren min da xue chu ban she, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

yong, Yang zong. 5 fen zhong ying de ren xin. Guang zhou: Guang dong jing ji chu ban she, 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

yu, Jiao. You yi zhong cai fu jiao cheng xin. Bei jing: Bei jing ta xue chu ban she, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Wei, Qingyue. Sheng huo zhong de xin li xue. Beijing: Di zhen chu ban she, 2006.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

xin, Li. Sheng huo zhong de xing wei xin li xue. Bei jing: Zhong guo shang ye chu ban she, 2014.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Zhong guo nan hai xin li cheng zhang zhen bian shu. Beijing: Zhong guo fu nu^ chu ban she, 2011.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

jiang, Wu man lan. Zhong guo ren de shi yong xin li xue. Tian jin: Tian jin ke xue ji zhu chu ban she, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Wo yu zhong bu tong, chuang zao bu tong: Who I am makes a difference. Taibei shi: Yuan liu chu ban shi ye gu fen you xian gong si, 2000.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Davies, Jacqueline. Ai xin tang shi jian. Wuhan: Zhang jiang shao nian er tong chu ban she, 2016.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Yinmeng, Hu, ed. Shi jie zai ni xin zhong. Shenzhen Shi: Shenzhen bao ye ji tuan chu ban she, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Actas de conferencias sobre el tema "Tong xin zhong xue"

1

Bai, Hao, Fujian Zhou, Junlin Wu, Bojun Li, Bin Wang, Hang Xu, Wenzhong Wang, Hao Lang, Erdong Yao y Jiachen Wang. "Preliminary Study on a Strong Sand-Carrying and Low Damage Viscoelastic Slickwater Under a Wide Shear Range". En 57th U.S. Rock Mechanics/Geomechanics Symposium. ARMA, 2023. http://dx.doi.org/10.56952/arma-2023-0184.

Texto completo
Resumen
ABSTRACT Slickwater or linear gel is often used for fracturing development in tight sandstone reservoirs. As it carries sand into the formation through the wellbore, its sand-carrying performance changes with the continuous change of liquid shear rates. In this paper, a new type of viscoelastic slickwater is proposed, which avoids the problems of low sand-carrying capacity of conventional slickwater and large damage of guar. Through theoretical calculation, taking the injection rate of 10 m3/min as an example, the maximum shear rate of fracturing fluid in wellbore and fracture is 884.82 s−1 and 8.33 s−1 respectively. Viscoelastic slickwater polymer is physically cross-linked and reversible associated to form a network structure. It has excellent shear resistance at different shear rates (0.01∼1000 s−1). The intersection point of viscoelastic modulus is lower than 0.021 Hz, and the viscoelastic performance is excellent. Under the low shear rates of fracture (0.01∼10 s−1), the performance of viscoelastic slickwater suspended sand is excellent, and the equilibrium height of sand bank is lower than 26.7% of fracture height. Under the high shear rates (10∼1000 s−1) in the wellbore, its viscosity is high, and the friction reduction rate can reach 81.59%. In addition, it breaks quickly, the amount of residue is low, and the conductivity can be retained by more than 90%. Under field application, the sand concentration of the system is as high as 300 kg/m3, and the production of vertical well after fracturing can reach 0.96 tons/day in more than one year. Viscoelastic slickwater can realize friction reduction and sand carrying at the same time, which has the value of popularization and application. INTRODUCTION The tight sandstone reservoir has features of tight lithology, low porosity, and low permeability, and others, mainly secondary porosity, and high feldspar and cuttings content. Due to low reservoir pressure coefficient, its natural productivity is low (Wang et al., 2022; Zhong et al., 2022). Compared with conventional reservoirs, tight sandstone reservoirs have staggered pore distribution and poor connectivity, high water saturation, strong stress sensitivity, and limited recovery by conventional oil displacement methods (Xie et al., 2022; Dong, et al.,2019). Therefore, new unconventional reservoir stimulation technologies and measures are urgently needed.
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías ampliadas sobre el tema "Tong xin zhong xue" para tipos de fuentes particulares:
Artículos de revistas Tesis Libros
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía